PSNL - Personalis, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
22.04
-0.55 (-2.43%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close 22.59
Open 22.30
Bid 20.16 x 1100
Ask 0.00 x 1400
Day's Range 21.71 - 22.43
52 Week Range 20.21 - 31.88
Volume 141,562
Avg. Volume 797,491
Market Cap 639.751M
Beta (3Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -6.57
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est 28.50
Trade prices are not sourced from all markets
  • 2 Small-Cap Biotech IPOs You Should Know About
    Motley Fool 6 days ago

    2 Small-Cap Biotech IPOs You Should Know About

    The public markets are awash in new biopharmaceutical companies, but these two appear to be overlooked.

  • 3 Top Stocks That Aren't On Wall Street's Radar
    Motley Fool 18 days ago

    3 Top Stocks That Aren't On Wall Street's Radar

    Wall Street might be overlooking these intriguing investing opportunities.

  • Business Wire last month

    Personalis Announces Closing of Initial Public Offering and Exercise in Full of Over Allotment Option

    Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the closing of its initial public offering of 9,109,725 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,188,225 additional shares of common stock. All of the shares of common stock were offered by Personalis. Personalis estimates net proceeds from the offering to be approximately $140.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.

  • Benzinga last month

    Personalis IPO: What You Need To Know

    Data analytics in the biotech realm comes in the form of genomic sequencing – the process of determining the complete DNA sequence of an organism's genome, which helps in developing personalized and targeted ...

  • Business Wire last month

    Personalis Prices Initial Public Offering of Common Stock

    Personalis, Inc., a leader in advanced genomics for cancer, today announced the pricing of its initial public offering of 7,921,500 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Personalis. In addition, Personalis has granted the underwriters a 30-day option to purchase up to an additional 1,188,225 shares of common stock from Personalis at the public offering price less underwriting discounts and commissions.

  • Benzinga last month

    IPO Outlook For The Week: Biotechs And A Grocery Outlet

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...